Published on | 4 years ago
Programmes Horizon EuropeThe European Commission has established six executive agencies which will all be located in Brussels. The executive agencies will assist the European Commission in the implementation of the Union programmes in the 2021-2027 multiannual financial framework (MFF), among others the European framework programme for research and innovation Horizon Europe, and in addition assist with the ongoing Horizon 2020 projects. The following five agencies are established from 1 April 2021 until 31 December 2028:
A new European Health and Digital Executive Agency (EHDEA) is established from 16 February 2021 until 31 December 2028 and follows-up on Horizon Europe pillar II cluster 1 (health) and cluster 4 (Digital, industry and space research). The Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) which is currently based in Luxemburg ceases to exist.
More details on the division of portfolios can be found in the European Commission implementing decision on the establishment of the executive agencies. This Nether news article includes a quick overview of each agency and their complete Horizon Europe portfolios.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.